-
Press ReleaseNew Novartis ESC data highlights strength of cardiovascular portfolio
-
Press ReleaseNovartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
-
Press ReleaseNovartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
-
Press ReleaseNovartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
-
Story
Drug delivery, service delivery, and the future of cancer care -
Story
Innovation fueled by compassion -
Story
Shoulder to shoulder -
Press ReleaseNovartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
-
Press ReleaseNovartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
-
Story
Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way -
Story
A scientist from the start – Q&A with NIBR President Fiona Marshall -
Story
Renewing our commitment to neglected tropical disease and malaria elimination